Peripheral Neuropathy Trial, Recruiting NCT06583122 Sponsor: University of Kansas Medical Center Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06583122
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between the ages of 18 and 80 who have been diagnosed with occipital neuralgia or migraines that are mainly felt in the back of the head.
  • People whose occipital neuralgia diagnosis meets standard medical criteria, meaning they experience sharp, stabbing pain at the back of the head, tenderness over the affected nerve, and their pain was relieved for at least 3 hours after a numbing injection near that nerve.
  • People diagnosed with migraines where most of the pain is at the back of the head, and whose pain responded to a nerve-blocking injection in that area.
  • People whose pain has not been adequately controlled by oral medications, including anti-inflammatory drugs, opioids, or anti-seizure medications (meaning those medications reduced pain by less than 50%).
  • People who experience headaches on at least 10 days per month.

Who may not be able to join:

  • People with an unstable medical or psychological condition.
  • People who are pregnant.
  • People who have an implanted heart pacemaker or defibrillator that cannot be switched off.
  • People who have previously had brain surgery or have scar tissue over the area at the back of the head where the procedure would be performed.
  • People who have had a spinal fusion surgery in the neck area.
  • People who have signs of raised pressure in the brain or a brain tumor.
  • People who have previously had radiofrequency ablation (a heat-based nerve treatment) of the nerves at the back of the head.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 913-588-6670

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
1 July 2022
Est. completion
30 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Reduction pain scores reported using an 11-point numeric rating scale (NRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov